In this webinar ViiV Healthcare’s team of experts present the differentiating features of dolutegravir-based regimens for the treatment of HIV, including the science behind a high barrier to resistance and the clinical implications.
Taking Resistance from the Bench Side to the Clinic: A Focus on Dolutegravir
Presented by Dr. Romina P. Querica, Global Director of Clinical Virology and Early Drug Development, ViiV Healthcare.
TRIUMEQ is indicated for the treatment of HIV-infected adults and adolescents above 12 years of age weighing at least 40kg.
Before initiating treatment with abacavir-containing products, HLA-B*5701 status must always be documented. Abacavir should not be used in patients known to carry the HLA-B*5701 allele due to the risk of hypersensitivity reaction.
Tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children above 6 years of age.